Clinical trials: Prostatic Adenocarcinoma
Prostate Cancer
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
The main object of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess impact of maintenance of orteronel on disease progression and hence on quality of life of patients with metastatic…
- Trial name
- NCT02053311
- Testing
- Orteronel
- Where
- 7 sites in Switzerland
- Sponsor
- Swiss Cancer Institute
Metastatic Castration-Resistant Prostate Adenocarcinoma
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration…
- Trial name
- NCT04077021
- Testing
- CCW702
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Calibr, a division of Scripps Research
Prostate Adenocarcinoma
Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.
- Trial name
- NCT03404648
- Testing
- C-11 choline PET tracer, Gadobutrol, PET/MR scanner
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer
RATIONALE: Imaging procedures such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) may improve the ability to detect the extent of prostate cancer.
- Trial name
- NCT00032058
- Testing
- magnetic resonance imaging, magnetic resonance spectroscopic imaging
- Where
- 8 sites in United States
- Sponsor
- American College of Radiology Imaging Network
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving…
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07466498
- Testing
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Cancer, Prostate Cancer
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554918
- Testing
- docetaxel, prednisolone, zoledronic acid
- Where
- 16 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University Hospital Birmingham
Prostatic Neoplasm
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
In current clinical practice, an acceptable standard treatment for locally advanced prostate cancer is radiation therapy in combination with hormone therapy (called Treatment B or Group B in this study).
- Trial name
- PREMIUM (NCT01996696)
- Testing
- Metformin
- Where
- 3 sites in Canada
- Volunteers
- 83 people
- Sponsor
- AHS Cancer Control Alberta
Pancreatic Adenocarcinoma, Adenosquamous Carcinoma
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroendocrine prostate carcinoma…
- Conditions
- Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT05988918
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan Rogel Cancer Center
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Prostate Cancer
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.
- Trial name
- PR05 (NCT01040624)
- Testing
- < 15% risk of + LN, > 15% risk of + LN
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Florida
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Prostate Adenocarcinoma
Prostate Cancer - Localized Adenocarcinoma Proton Therapy
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma
- Trial name
- NCT03285815
- Testing
- Proton Therapy
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- National Cancer Center, Korea
Breast Carcinoma, Cholangiocarcinoma
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer.
- Conditions
- Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT03563352
- Testing
- Interview, Survey Administration
- Where
- United States
- Sponsor
- University of Southern California
Colorectal Carcinoma, Rectal Prolapse
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic…
- Conditions
- Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer
- Trial name
- NCT06926374
- Testing
- Robotic surgery using the Sentire Surgical System
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese University of Hong Kong
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Metastatic Prostate Cancer
Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines
The purpose of this research is to develop a new and powerful type of immune therapy for prostate cancer patients. This therapy involves vaccinations with special stimulator cells found in the human body called dendritic cells.
- Trial name
- NCT01153113
- Testing
- hTERT mRNA DC
- Sponsor
- University of Florida
Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants…
- Conditions
- Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
- Trial name
- NCT07488923
- Testing
- ML261
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- Moonlight Bio, Inc
Prostate Cancer, Prostate Adenocarcinoma
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
The study is a non-randomized, prospective trial of men scheduled for radical prostatectomy for treatment of prostate cancer as standard of care and will undergo a series of pre-operative multi-modality imaging studies.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
- Trial name
- IGPC-5 (NCT04053842)
- Testing
- PET Scan, [18F]PSMA-1007 Injection, Sodium MRI
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Glenn Bauman
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
This pilot phase II trial studies how well giving bevacizumab works in treating patients with relapsed prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01656304
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
Ga-68-PSMA-11 in Men With Prostate Cancer
The purpose of this study is to provide access to Ga-68-PSMA-11 PET for evaluation of male veterans with newly diagnosed or biochemically recurrent prostate cancer.
- Trial name
- Ga68-PSMA-11 (NCT05744115)
- Testing
- Ga-68-PSMA-11
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Timothy Hoffman
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.